Q3 2025 13F Holders as of 9/30/2025
-
Type / Class
-
Equity / Common Stock, par value $0.01 per share
-
Shares outstanding
-
16.8M
-
Number of holders
-
28
-
Total 13F shares, excl. options
-
1.91M
-
Shares change
-
+461K
-
Total reported value, excl. options
-
$20.9M
-
Value change
-
+$5.12M
-
Number of buys
-
19
-
Number of sells
-
-4
-
Price
-
$10.94
Significant Holders of Elicio Therapeutics, Inc. - Common Stock, par value $0.01 per share (ELTX) as of Q3 2025
33 filings reported holding ELTX - Elicio Therapeutics, Inc. - Common Stock, par value $0.01 per share as of Q3 2025.
Elicio Therapeutics, Inc. - Common Stock, par value $0.01 per share (ELTX) has 28 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 1.91M shares
of 16.8M outstanding shares and own 11.39% of the company stock.
Largest 10 shareholders include Knoll Capital Management, LLC (631K shares), VANGUARD GROUP INC (474K shares), Balyasny Asset Management L.P. (148K shares), GEODE CAPITAL MANAGEMENT, LLC (130K shares), SUSQUEHANNA INTERNATIONAL GROUP, LLP (120K shares), MARSHALL WACE, LLP (86.5K shares), NORTHERN TRUST CORP (53.6K shares), RENAISSANCE TECHNOLOGIES LLC (48.7K shares), BlackRock, Inc. (44.2K shares), and STATE STREET CORP (38.3K shares).
This table shows the top 28 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.